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ess: l.vandentoorn@plaSummary Study objectives: Subjects with atopic asthma often experience a
disappearance of symptoms around puberty. However, airway inflammation and
remodeling may persist. It is unknown whether those findings warrant prolonged
anti-inflammatory treatment despite the absence of symptoms. In this study, we
investigated whether a short course of combined anti-inflammatory treatment
would, also in this specific patient population, diminish airway inflammation and/or
remodeling.
Design: A double-blind, randomized placebo-controlled trial was conducted in 28
asymptomatic subjects with a history of atopic asthma, with established bronchial
hyperresponsiveness to methacholine (MCh) as non-invasive indicator of ongoing
airway pathology.
Interventions: Intervention consisted of the salmeterol/fluticasone propionate
combination (SFC) product (50/250 mg bid via the DiskusTM inhaler) or placebo for 3
months.
Measurements: The change in lung function (FEV1), bronchial response to MCh
and adenosine monophosphate (AMP), the fraction of nitric oxide in exhaled air
(FENO) and quality of life (QOL) scores were measured. Also, bronchial biopsies were
taken and cryo sections immunostained for eosinophils (major basic protein, MBP)
and mast cells (tryptase and chymase) before and after treatment. The change inElsevier Ltd. All rights reserved.
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L.M. van den Toorn et al.780reticular basement membrane (RBM) thickness, one of the parameters of airway
remodeling, was also determined.
Results: SFC treatment improved hyperresponsiveness to MCh ðP ¼ 0:014Þ as well
as AMP ðP ¼ 0:011Þ; and reduced FENO ðPo0:001Þ significantly as compared with
placebo. Lung function tended to improve (NS). Furthermore, SFC treatment
reduced tryptase in the subepithelium of bronchial biopsy specimens ðP ¼ 0:01Þ; and
slightly reduced RBM thickness ðP ¼ 0:05Þ: However, eosinophils in (sub)epithelium
were not significantly affected; neither were chymase levels, blood eosinophils or
QOL scores.
Conclusions: We found that 3 months of treatment with fluticasone propionate
and salmeterol reduced airway hyperresponsiveness, FENO and tryptase density in
the airway mucosa as markers of airway inflammation. MBP density in the airway
mucosa and QOL were, however, unchanged. The clinical relevance of these findings,
especially with respect to the long-term outcome, has not been determined yet.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Atopic asthma commonly starts in childhood and
often seems to disappear in early adolescence.1,2
The term ‘‘clinical remission’’ is widely used to
identify subjects with apparently outgrown asth-
ma. Unfortunately, a substantial proportion those
subjects will have a relapse later in life, mostly
before the age of 30.2 Recently, airway inflamma-
tion and structural airway changes were demon-
strated in airway biopsy specimens and
bronchoalveolar lavage (BAL) fluid from young
adults with a longstanding clinical remission of
atopic asthma.3,4 Ongoing inflammation and remo-
deling possibly contribute to irreversible airway
narrowing5 and bronchial hyperresponsiveness,
thereby probably providing a basis for a future
relapse of asthma.
It is unclear whether the long-term prognosis of
subjects in clinical remission of asthma, but with
evidence of ongoing disease, can be altered
positively with prolonged anti-inflammatory ther-
apy. There is ample evidence that inhaled steroids
decrease airway inflammation,6 whereas the effect
on remodeling is less evident.7,8 An effect on
subepithelial collagen deposition9 and airway wall
vascularity10 was, however, documented. It has also
been shown that in very mild asthmatic subjects,
anti-inflammatory therapy with fluticasone propio-
nate reduces airway inflammation and remodeling
after 3 and 12 months of therapy, respectively.11
Besides, De Kluijver12 demonstrated that low-dose
allergen exposure in asymptomatic asthmatic sub-
jects led to airway inflammation without worsening
of symptoms, which could be prevented by inhaled
steroid treatment. Hence, the question is whether
persistent airway inflammation and remodeling
warrant the use of prolonged anti-inflammatory
treatment in otherwise asymptomatic subjects with
a history of atopic asthma.9,13,14 To provide ananswer to this question, it should at first and
foremost be evaluated whether anti-inflammatory
therapy indeed has a direct diminishing effect on
airway inflammation and/or remodeling in this
specific patients’ population. Subsequently, future
studies should elucidate whether prolonged anti-
inflammatory therapy will positively alter the long-
term prognosis from subjects in clinical remission of
asthma.
When it comes to the treatment of choice, there
is a rationale for combining inhaled steroids with
long-acting b2-agonists (LABAs) in the present study
population. After all, a novel anti-neutrophilic
effect of the LABA salmeterol in mild asthma has
been reported recently,15 next to an anti-eosino-
philic effect of the LABAs salmeterol16 and for-
moterol.17
Therefore, it was the aim of this study to
investigate the effect of a short course of combina-
tion treatment with salmeterol and fluticasone
propionate on indices of airway inflammation and
remodeling in young adults in longstanding clinical
remission of atopic asthma, who had hyperrespon-
siveness to methacholine (MCh) as non-invasive
indicator of ongoing airway disease.Subjects, study design and methods
Subjects
Young adults, 18–30 years of age, were selected
from the Sophia Children’s Hospital discharged
atopic asthma patients files. Clinical remission of
atopic asthma was defined as to two independent
investigators repeatedly reported complete ab-
sence of asthmatic symptoms while not taking any
asthma or allergy medication for at least 12 months
prior to the study. Subjects with perennial rhinitis
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nosed as having atopic asthma according to ATS
criteria.18 All subjects were lifelong non-smokers in
stable clinical condition. We conducted a double-
blind, parallel-group, randomized placebo-con-
trolled trial in 28 subjects who were in clinical
remission of atopic asthma for a median duration of
5 years, with a cumulative provocative doses
causing a 20% fall in FEV1 (PD20) MCh cumulative
less than or equal to 7.8 mmol at the beginning of
the study as non-invasive indicator of ongoing
airway disease.
The study was approved by the Medical
Ethics Committee of the Erasmus Medical Center
Rotterdam.Study design
All subjects underwent non-invasive and invasive
measurements on three visits within 3 weeks,
followed by a 3-months’ intervention period, after
which all measurements were repeated on three
visits. At the first visit, subjects gave written
informed consent and were asked about asthmatic
symptoms and requirement of rescue medication
during the past year, especially in order to avoid
the inclusion of subjects with mild asthma. Also,
quality of life (QOL) scores were obtained. There-
after, physical examination was performed and the
fraction of exhaled NO (FENO) and PD20 MCh
determined. At visit 2, scheduled at least 1 day
after visit 1, subjects underwent an adenosine
monophosphate (AMP) challenge test. At visit 3,
scheduled at least 3 days, but not more than 2
weeks, after visit 2, FEV1 and FEV1 reversibility
were tested, followed by venapunction and flexible
bronchoscopy. The sequence and intervals were
chosen in order to avoid any influence of the AMP
challenge on MCh responsiveness and/or on FEV1.
19
For analysis of a specific variable, only data from
subjects with pre- as well as post-treatment values
were used.
Spirometry values, MCh- and AMP-responsive-
ness, FENO and blood eosinophils were obtained
according to methods described earlier.20 These are
summarized briefly hereafter. Methods of obtaining
QOL scores as well as collecting and processing
bronchial biopsies are described in more detail.
Intervention consisted of the salmeterol/flutica-
sone propionate combination (SFC) product (250/
50 mg bid via the DiskusTM inhaler) or placebo for 3
months72 weeks. Therapy adherence and adverse
effects were recorded by the primary investigator.
If more than 85% of the totally prescribed numberof doses was emptied out of the device, therapy
adherence was arbitrarily considered adequate.
Bronchial hyperresponsiveness
Challenge tests were performed according to the
dosimeter method validated by Birnie et al.21 Study
medication was not allowed within 36 h prior to the
test. After recording baseline values, the challenge
started with inhalation of NaCl 0.9%. Inhalation
provocation tests were performed using doubling
concentrations of 0.15–78.4mg/ml MCh bromide in
PBS or 0.08–160mg/ml AMP in normal saline (Sigma
Chemical Co., St. Louis, MO, USA). PD20 from
baseline were calculated by means of linear
interpolation of the logarithmic dose–response
curve. If FEV1 fell less than 20% of the pre-
challenge level at the highest dose administered,
twice the cumulative total inhaled dose was
arbitrarily used as the PD20 value.
Spirometry
Study medication was not allowed within 36 h prior
to the test. Flow–volume curves were obtained
using a Lilly-type pneumotachograph (Masterlab
Jaeger, Wu¨rzberg, Germany). The best of three
reproducible recordings of FEV1 was expressed as
percentage of predicted normal and used for
analysis. Reversibility was tested by measuring
FEV1 before and 20min after inhalation of 1mg of
terbutaline powder (Bricanyl turbuhaler, ASTRA,
Lund, Sweden), and expressed as increase in
percentage of predicted normal.
Fraction of nitric oxide in exhaled air
FENO was measured in exhaled air by means of
chemiluminescence (model 280 nitric oxide analy-
zer, Sievers, Boulder, CO) according to recommen-
dations of a European Respiratory Society Task
Force.22 Subjects inhaled to TLC and immediately
exhaled for as long as possible into a tube with an
in-line flow resistor (20 cm H2O/l/s, Rudolph, MO).
This was done at a flow corresponding to 5% of the
subjects’ vital capacity per second.
Bronchoscopy
Premedication consisted of terbutaline 1mg by
metered dose inhaler and atropine 500 mg intra-
muscularly. After topical anesthesia with oxybu-
procaine 10mg/ml to a maximum of 20ml, and
xylocaine 10%, an Olympus model BF IT 10 (Tokyo,
Japan) was passed by oral route. All bronchoscopies
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(S.E.O.). At least five bronchial biopsies were
obtained with the Olympus Swing Jaw forceps from
segmental divisions of the main bronchi at both
occasions.
Processing of bronchial biopsies
Bronchial biopsies were embedded in Tissue-Tek II
OCT medium (Miles, Naperville, IL), snap frozen in
liquid nitrogen and stored at 80 1C. Serial tissue
sections (6 mm) were cut on an HM-560 cryostat
(Microm, Heidelberg, Germany). At least two
sections 120 mm apart from one biopsy specimen
were placed on a poly-L-lysine-coated microscopic
slide (Sigma Diagnostics, St. Louis, MO). Immunos-
taining was carried out with a-major basic protein
(MBP, Sanbio BV, Uden, The Netherlands), a-
tryptase and a-chymase (Chemicon Brunschwig
Chemie, Amsterdam, The Netherlands). Binding of
the antibodies was detected by the immuno-alka-
line phosphatase anti-alkaline phosphatase (APAAP)
method. Immunostained sections were analyzed
with an image analysis system (Quantimed, Leica,
Rijswijk, The Netherlands). With respect to the
subepithelium, the program was set to analyze
100 mm below the reticular basement membrane
(RBM). The ratio of positive stained area divided by
the total area analyzed was taken as measure for
each immunohistochemical staining. RBM thickness
was interactively measured at 20 mm intervals over
a 1mm RBM length.23
Quality of life
QOL scores were obtained with the aid of a
modified RAND Health Insurance Study Question-
naire,24 the so-called RAND 36-item Health Survey,
Dutch Version. RAND 36 consists of eight different
categories of general health, that is to say physical
functioning, social functioning, role limitations,
emotional problems, mental health, pain, generalTable 1 Subjects’ characteristics.
SFC
n (male) 14 (11)
Age (year) 19.6 (1
FEV1 (% pred.) 94.1 (6
FEV1 reversibility (%) 9.9 (0–
PD20 MCh (mmol) 1.7 (0.
PD20 AMP (mmol) 24.0 (1
Exhaled NO (ppb) 11.9 (7
Note: SFC, salmeterol/fluticasone propionate combination.
All variables but FENO (median; range) are expressed as means (health perception and health change. Items are
scored 1–5 or 6. A higher score means better
health. In each category, 100 is the maximum total
score.
Statistical analysis
Lung function data (FEV1, FEV1 reversibility, PD20
MCh and PD20 AMP) and QOL data (RAND 36) were
parametrically analyzed using ANCOVA, where the
baseline measurement of the outcome variable
considered was included as covariant in comparing
the two treatment groups (SFC and placebo).
Within-subject changes from baseline of these
variables were tested using the paired t-test for
either treatment group. For the PD20 variables, the
analyses were done after log2 transformation. PD20
MCh was used as primary variable. Power calcula-
tions were based on this variable, where a number
of 14 subjects in each group was supposed sufficient
to show a difference of two doubling doses between
the treatment groups in the within-subject changes
from baseline. The other outcome variables were
analyzed by comparing changes from baseline
between the two treatment groups using the
Mann–Whitney test. Within-subject changes from
baseline of these other variables were tested using
the Wilcoxon signed rank test for either treatment
group. P-values below 0.05 were used to indicate
statistical significance.Results
Both the SFC group and the placebo group consisted
of 14 subjects. Groups were well matched with
respect to age, sex, FEV1, FEV1 reversibility,
bronchial response to MCh and AMP, and FENO
(Table 1). One asymptomatic (!) subject in the SFC
group showed a pre-trial FEV1 of 63% and an FEV1
reversibility of 31%. All other subjects in both
treatment groups had a pre-trial FEV1 above 80%,Placebo
14 (9)
8–23) 20.4 (18–24)
3–119) 101.2 (87–120)
31) 6.9 (0–23)
1–6.2) 3.3 (0.3–7.4)
.0–60.5) 23.1 (1.4–60.5)
.2–22.0) 9.5 (4.0–23.4)
range).
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Figure 1 PD20 MCh values pre- and post-treatment for 3
months with the SFC product (n ¼ 14)) or placebo ðn ¼
14Þ: Each line represents one subject. Non-responders are
arbitrarily given a value of twice the highest cumulative
dose given. Horizontal bars represent mean values.
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Figure 2 PD20 AMP values pre- and post-treatment for 3
months with the SFC product (n ¼ 14)) or placebo ðn ¼
14Þ: Each line represents one subject. Non-responders are
arbitrarily given a value of twice the highest cumulative
dose given. Horizontal bars represent mean values.
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Figure 3 Exhaled nitric oxide levels pre- and post-
treatment for 3 months with the SFC product (n ¼ 12)
or placebo ðn ¼ 12Þ: Each line represents one subject.
Horizontal bars represent median values.
Benefit from anti-inflammatory treatment 783and clearly lower reversibility. One subject in the
placebo group refused the second bronchoscopy
because of a negative experience with the first
one. One other subject, also in the placebo group,
could not undergo bronchoscopy because of a
bleeding disorder. Therapy adherence was consid-
ered adequate since none of the subjects had used
less than 85% of the prescribed total number of
doses. Both treatments were well tolerated.
SFC treatment for 3 months significantly im-
proved PD20 MCh (P ¼ 0:014; Fig. 1) as well as PD20
AMP (P ¼ 0:011; Fig. 2), and reduced FENO
(Po0:001; Fig. 3). Furthermore, SFC treatment
reduced tryptase-positive cells in the bronchialsubepithelium (P ¼ 0:01; Figs. 4 and 5), whereas
MBP-positive cells in both the epithelium and
subepithelium decreased slightly, but not signifi-
cantly (Fig. 6). Following SFC treatment, thickness
of the RBM was reduced slightly (P ¼ 0:05; Fig. 7).
Compared to placebo, FEV1 and FEV1 reversibility,
blood eosinophils, chymase density in bronchial
biopsies and QOL scores did not change as a result
of 3 months of SFC treatment.Discussion
The majority of subjects in clinical remission of
atopic asthma show ongoing airway inflammation
and remodeling,3,4 which may predispose for a
relapse later in life. The present study shows that
combined treatment with an inhaled steroid and a
LABA significantly reduces bronchial hyperrespon-
siveness and FENO levels after 3 months of therapy.
Except for the change in tryptase density, no
significant changes were demonstrated of invasively
obtained markers of inflammation and remodeling.
Anti-inflammatory treatment normalized both
MCh responsiveness and AMP responsiveness in a
substantial proportion of the subjects in the study.
Where AMP responsiveness is believed to be related
to active airway inflammation by inducing mast cell
degranulation, MCh acts through direct mechan-
isms on the airway smooth muscle, thereby
probably at least in part reflecting structural
changes, i.e. airway remodeling, in the airways.25
We recently found a significant relationship be-
tween AMP responsiveness and eosinophilic airway
inflammation.3 Hence, a normal response to AMP
suggests the absence of clinically significant active
ARTICLE IN PRESS
Figure 4 Example of a biopsy specimen pre- (a) and post-
treatment (b) from a subject in clinical remission with
tryptase staining (mast cells) in red.
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Figure 5 Tryptase density in the bronchial subepithelium
pre- and post-treatment for 3 months with the SFC
product (n ¼ 10) or placebo ðn ¼ 11Þ: Each line repre-
sents one subject. Horizontal bars represent median
values.
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Figure 6 MBP density in the bronchial subepithelium pre-
and post-treatment for 3 months with the SFC product
(n ¼ 11) or placebo ðn ¼ 11Þ: Each line represents one
subject. Horizontal bars represent median values.
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Figure 7 Thickness of the RBM pre- and post-treatment
for 3 months with the SFC product (n ¼ 8) or placebo
ðn ¼ 11Þ: Each line represents one subject. Horizontal
bars represent median values.
L.M. van den Toorn et al.784inflammation.26 Normal MCh responsiveness, on the
other hand, possibly relates to the absence of
manifest structural changes in the airways as well.
In a study of Koh et al.,27 BHR to MCh was
unchanged in subjects in clinical remission of
asthma after 9 months of treatment with inhaled
budesonide. Whether this was due to more severe
and irreversible airway changes, or a different kind
of study medication as compared to our treatment,
is unclear. Thus, both MCh and AMP challenge might
be useful in monitoring airway disease activity and
response to treatment.
A highly significant reduction in FENO levels was
seen. More specifically, 10 out of 12 subjects
treated with SFC reached FENO values less than
8 ppb after 3 months of treatment. It has been
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airway mucosal eosinophilia,3,28 BAL eosinophils29
and sputum eosinophils in atopic asthma,30
although others did not find such a relationship.31
Therefore, next to MCh- and AMP-responsiveness,
FENO might be a useful tool in monitoring disease
activity and effectiveness of treatment.32–34
Furthermore, our data suggest that FENO could be
a more rapidly responding marker of active
inflammation than are tissue eosinophils.
With respect to markers of airway inflammation
in tissue specimens, only tryptase levels improved
significantly. Since a central role in the inflamma-
tory process including airway remodeling has been
attributed to bronchial mast cells,35,36 the demon-
strated effect of anti-inflammatory therapy on
these cells may be of clinical relevance. Changes
in MBP density, reflecting eosinophil activity,
showed a trend toward a reduction in the SFC
group, but were not significant. We speculate that
MBP changes might reach significance when more
subjects would have been studied, which might be
also true for changes in chymase.
We found that the thickness of the RBM, one of
the characteristics of airway remodeling, was
reduced after treatment in some subjects, but
not in all. Overall changes were of borderline
significance. It can be argued that these changes
may be the result of reduction in RBM edema due to
plasma leakage,14,37,38 which might also be influ-
enced by the addition of a LABA to the study
medication.10 Ward et al.11 recently demonstrated
a significant effect of fluticasone propionate on
thickness of the RBM after 9 months of treatment in
subjects with mild asthma. Other characteristics of
airway remodeling, such as subepithelial collagen
deposition and smooth muscle hyperplasia, pre-
sumably respond more slowly, if at all.8,9 There-
fore, our intervention may have been too short to
induce important changes in the RBM thickness.
The choice of salmeterol plus fluticasone propio-
nate was arbitrarily based on the concept of
combination treatment as therapy of choice in
treating airway inflammation in asthma. In recent
years, an additive or even synergistic effect of
LABAs on airway inflammation15–17 and airway
vascularity10 has been documented. Also, LABAs
can improve well-being by providing immediate
relief by means of bronchodilation. As we found no
evidence of subjective improvement or better QOL
in this study, the added value of the LABA in
subjects with subclinical asthma remains concep-
tual. It was, however, the purpose to provide
‘‘optimal’’ treatment, not to elucidate whether
the same results could have been achieved with
inhaled steroids alone.The present study also demonstrates that the
improvement in bronchial hyperresponsiveness,
FENO values and mast cell activation is not
accompanied by improved QOL. Although QOL
seemed to be normal from the beginning of the
study, it could well have been that, as a result of
adaptation, subjects mistakenly considered them-
selves in excellent condition, which could have
changed after therapy. We previously reported that
the perception of acute onset airflow obstruction
was intact in subjects in clinical remission of
asthma.3 Presumably, slow changes in the degree
of airway inflammation and remodeling are not well
perceived by asthmatic subjects. Especially in
patients with asthma in clinical remission or with
mild asthma, this has important implications for
the way we make treatment decisions, as the
presence of symptoms is obviously not a sensitive
indicator of ongoing disease.
The clinical implications of our study seem to be
rather complicated. It can be argued that we have
just investigated ‘‘bad perceivers’’, but it must be
kept in mind that the study subjects did not use any
medication, did not visit a doctor, and were
convinced that they had outgrown their asthma
for many years, meaning that nothing would have
done with them if this study was not undertaken.
We could demonstrate that the effects of our
intervention on hyperresponsiveness, FENO and
tissue tryptase were significant and, since these
variables reflect airway inflammation, might be
beneficial to the patient. Any effect on the long-
term prognosis is, however, unclear. At now, it has
not been demonstrated that aggressive anti-inflam-
matory treatment during clinical remission has
advantages over a ‘‘wait and see’’ strategy. How-
ever, a slow but steady decline in lung function
during clinical remission could possibly be pre-
vented with, perhaps low-dose, anti-inflammatory
therapy. Furthermore, it is questionable whether
subjects who have no subjective benefit from
treatment will continue to take prescribed inhaled
steroids for an unspecified time, since adherence
with treatment is already a worry in patients with
symptomatic asthma. However, if future studies
demonstrate that prolonged anti-inflammatory
treatment will positively alter the long-term prog-
nosis in subjects in clinical remission of asthma,
treatment might be justified and can be discussed
with the patient. Also, a positive effect should
counterbalance occurring side effects of prolonged
therapy.
In conclusion, we found that 3 months of
treatment with fluticasone propionate and salme-
terol reduced airway hyperresponsiveness, FENO
and tryptase density in the airway mucosa as
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airway mucosa and QOL were, however, un-
changed. The clinical relevance of these findings,
especially with respect to the long-term outcome,
has not been determined yet.Acknowledgements
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